The use of the drug gemcitabine for chemotherapy significantly delays the recurrence of pancreatic cancer compared to no chemotherapy, a study has shown.
Research conducted in a sample of 386 patients with pancreatic cancer found patients were less likely to have recurrent cancer after treatment with gemcitabine.
In the 179 patients treated with the drug, 74.3% had recurrent cancer. Among the 175 patients in the control group, who did not receive the drug, 92% had recurrent cancer.
Estimated disease-free survival at three and five years was 23.5% and 16.5% in the gemcitabine group and 7.5% and 5.5% in the control group respectively.
Journal of the American Medical Association (2007) 297: 267-277